Use of hydrolytic and oxidative enzymes to dissolve biofilm in airway passages
A composition for removal of biofilm in the airway passage is useful for the treatment of infections such as pneumonia cause by Mycoplasma pneumoniae . In general, the composition comprises: (1) a quantity of at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in the airway; and (2) a pharmaceutically acceptable carrier suitable for administration into the airway. The composition can further include ingredients such as a steroid, lysozyme, lactoferrin, or a peroxidase; if a peroxidase is included, the composition can further include an oxidase to generate peroxide as well as a substrate for the oxidase. The composition can be used in methods for treatment of an infection based on the ability of the composition to dissolve biofilm in the airway.
1. A method of dissolving biofilm present in an airway infection comprising administering a therapeutically effective amount of a composition to an individual in need thereof, wherein the composition comprises effective amounts of lysozyme, lactoferrin and at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down biofilm in airway passages, wherein the composition is formulated to target the biofilm.
2. The method of claim 1 , wherein the composition further comprises at least one steroid selected from the group consisting of hydrocortisone, beclomethasone, budesonide, ciclesonide, flunisolide, fluticasone, methylprednisone, prednisolone, prednisone, and triamcinolone.
3. The method of claim 1 , wherein the composition thither comprises a pharmaceutically acceptable carrier suitable for administration into the airway passages selected from the group consisting of water, ethanol and a polyol.
4. The method of claim 3 , wherein the pharmaceutically acceptable carrier suitable for administration into the airway passages includes propylene glycol, glycerol, or tripropylene glycol.
5. The method of claim 1 , wherein the composition further comprises an amount of an antibiotic that is effective against bacteria underlying the airway infection.
6. The method of claim 5 , wherein the antibiotic is delivered in a quantity effective to exert a bactericidal action against Mycoplasma pneumoniae , further wherein the antibiotic is selected from the group consisting of amikacin, ticarcillin, piperacillin, mezlocillin, ceftazidime, cefepime, ciprofloxacin, tobramycin, aztreonam, imipenem, and meropenem.
7. The method of claim 1 , wherein the composition further comprises at least one peroxidase in a quantity sufficient to exert a bactericidal action.
8. The method of claim 7 , wherein the at least one peroxidase is selected from the group consisting of lactoperoxidase, myeloperoxidase, horseradish peroxidase, eosinophil peroxidase, and glutathione peroxidase.
9. The method of claim 1 , wherein the composition further comprises at least one substrate that can be converted to an ion with bactericidal properties by the enzymatic action of the peroxidase in a quantity such that an effective concentration of the ion with bactericidal properties is produced by the catalytic action of the peroxidase.
10. The method of claim 9 , wherein the at least one substrate is an alkali metal salt of thiocyanate, iodate, or chlorate.
11. The method of claim 9 , wherein the composition further comprises an aminohexose in a quantity effective to increase the yield or accumulation of oxidized anionic biocidal agent.
12. The method of claim 1 , wherein the composition further comprises an oxidase selected from the group consisting of glucose oxidase, galactose oxidase, urate oxidase, choline oxidase, D-amino acid oxidase, D-glutamate oxidase, glycine oxidase, glycolic oxidase, L-sorbose oxidase, alcohol oxidase, and amine oxidase.
13. The method of claim 1 , wherein the composition is delivered to the individual via a route of administration selected from the group consisting of oral, sublingual, buccal, and nasal.
14. A method of treating an airway infection in the lung of an individual having a quantity of biofilm in an airway passage associated with the airway infection, the method comprising:
administering a therapeutically effective amount of a composition to the individual, wherein the composition comprises effective amounts of lysozyme, lactoferrin, and at least one enzyme that catalyzes the hydrolysis of a bond that connects two monosaccharides in a polysaccharide or that connects a monosaccharide with a protein molecule in a glycoprotein sufficient to break down the biofilm in the airway passage.
15. The method of claim 14 , wherein the airway infection is caused by Mycoplasma pneumoniae.
16. The method of claim 14 , wherein the composition further comprises an antibiotic that targets a bacteria associated with the airway infection and is administered to the individual by a route of administration other than nasal.
17. A method of treating an airway infection characterized by a biofilm formation in an individual suffering therefrom, the method comprising administering a therapeutically effective amount of a formulation to the individual, wherein the formulation comprises lysozyme, lactoferrin, and lactoperoxidase in amounts effective to dissolve the biofilm formation.
18. The method of claim 17 , further comprising, after administering the formulation, administering an antibiotic to the individual.